24 October 2025
: Case report 
Medical Management of an Infusion Site Extravasation Injury After Peripheral Intravenous Infusion of Ado-Trastuzumab Emtansine in a 38-Year-Old Woman With Breast Cancer: A Case Report
Unusual clinical course, Adverse events of drug therapy
Eleni M. Gamvroulas BDEF 1*, Patricia Jeppson E 1, Mei Wei
ADEF 2
DOI: 10.12659/AJCR.949828
Am J Case Rep 2025; 26:e949828
Figure 1 A 38-year-old woman with infusion site extravasation injury following intravenous treatment with trastuzumab-emtansine (T-DM1). Six days after initial insult, her skin is swollen and erythematous with varying degrees of pigmentation, but the skin is still intact. At this point, the patient received antibiotics and topical wound care for management.